Prospective, Longitudinal Study on Specific Cellular Immune Responses after Vaccination with an Adjuvanted, Recombinant Zoster Vaccine in Kidney Transplant Recipients

Lindemann, Monika; Baumann, Charleen; Wilde, Benjamin; Gäckler, Anja; Meller, Lara; Horn, Peter A.; Krawczyk, Adalbert; Witzke, Oliver

doi:10.3390/vaccines10060844

Cited by 7 publications

(4 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, as the ELISpot assay used PBMCs and not T-cell subpopulations, we cannot prove this hypothesis. As expected, T-cell immunity in patients with better kidney function was stronger, as has been observed previously in kidney transplant recipients after vaccination [38]. Adoptively transferred VSTs generated from eligible donors could provide broad antiviral protection to recipients of HSCT, including infections from BKV or other virus-related pathogens with low side effects, and appears to be an effective approach to treat severe viral infection [17].…”

Section: Discussionsupporting

confidence: 78%

Long-Term Follow-Up after Adoptive Transfer of BK-Virus-Specific T Cells in Hematopoietic Stem Cell Transplant Recipients

et al. 2023

Self Cite

View full text Add to dashboard Cite

The BK virus (BKV) causes severe hemorrhagic cystitis in hematopoietic stem cell transplant (HSCT) recipients. To eliminate reactivated BKV, symptomatic patients can be treated with a reduction of the immunosuppressive therapy, with the antiviral drug cidofovir, or with virus-specific T cells (VSTs). In the current study, we compared the effect of VSTs to other treatment options, following up specific T cells using interferon-gamma ELISpot assay. We observed BKV large T-specific cellular responses in 12 out of 17 HSCT recipients with BKV-related cystitis (71%). In recipients treated with VSTs, 6 out of 7 showed specific T-cell responses, and that number in those without VSTs was 6 out of 10. In comparison, 27 out of 50 healthy controls (54%) responded. In HSCT recipients treated for BKV-related cystitis, absolute CD4+ T-cell numbers and renal function correlated with BKV-specific cellular responses (p = 0.03 and 0.01, respectively). In one patient, BKV-specific cellular immunity could already be detected at baseline, on day 35 after HSCT and prior to VSTs, and remained increased until day 226 after VSTs (78 vs. 7 spots increment). In conclusion, the ELISpot appears to be suitable to sensitively monitor BKV-specific cellular immunity in HSCT recipients, even early after transplantation or in the long term after VSTs.

show abstract

Section: Discussionsupporting

confidence: 78%

Long-Term Follow-Up after Adoptive Transfer of BK-Virus-Specific T Cells in Hematopoietic Stem Cell Transplant Recipients

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, the vaccine’s high price may limit its general use in the aging population. The results of more large randomized trials and long-term studies are needed to evaluate its efficacy and safety in SOT practice [ 173 , 174 ].…”

Section: Future Perspectivesmentioning

confidence: 99%

Current Perspectives on the Management of Herpesvirus Infections in Solid Organ Transplant Recipients

Malahe

Kampen

Manintveld

et al. 2023

Viruses

View full text Add to dashboard Cite

Solid organ transplant recipients (SOTRs) are at high risk of human herpesvirus (HHV)-related morbidity and mortality due to the use of immunosuppressive therapy. We aim to increase awareness and understanding of HHV disease burden in SOTRs by providing an overview of current prevention and management strategies as described in the literature and guidelines. We discuss challenges in both prevention and treatment as well as future perspectives.

show abstract

“…In immunocompetent individuals, the RZV has been shown to elicit robust IgG and CD4 + T cell responses associated with strong and long-lasting immune protection 17 18. Immunogenicity of RZVs was also documented in several groups of immunocompromised patients including adults with an HIV infection,19 after renal transplantation20 21 or adult patients after autologous stem cell transplantation 22 23. Immunogenicity and potential correlates of RZV vaccine-induced immune protection are not known in patients with an increased risk of shingles due to an impaired immune function of the liver or post-LTx.…”

Section: Introductionmentioning

confidence: 99%

Tiza–Titre increase and enhanced immunity through an adjuvanted, recombinant herpes zoster subunit vaccine in patients with liver cirrhosis and post-liver transplantation: a study protocol for a prospective cohort study

Vollmer-Raschdorf,

Rashidi-Alavijeh,

Voigt

et al. 2023

BMJ Open

View full text Add to dashboard Cite

IntroductionShingrix, an effective adjuvanted, recombinant herpes zoster vaccine (RZV), has been available since 2018. Immunocompromised patients are known to be predisposed to vaccine failure. In-vitro testing of immunological surrogates of vaccine protection could be instrumental for monitoring vaccination success. So far, no test procedure is available for vaccine responses to RZV that could be used on a routine basis.Methods and analysisThis is a single-centre, three-arm, parallel, longitudinal cohort study aspiring to recruit a total of 308 patients (103 with a liver cirrhosis Child A/B, 103 after liver transplantation (both ≥50 years), 102 immunocompetent patients (60–70 years)). Blood samples will be taken at seven data collection points to determine varicella zoster virus (VZV) and glycoprotein E (gE)-specific IgG and T cell responses. The primary study outcome is to measure and compare responses after vaccination with RZV depending on the type and degree of immunosuppression using gE-specific antibody detection assays. As a secondary outcome, first, the gE-specific CD4+T cell response of the three cohorts will be compared and, second, the gE-VZV antibody levels will be compared with the severity of possible vaccination reactions. The tertiary outcome is a potential association between VZV immune responses and clinical protection against shingles.Ethics and disseminationEthical approval was issued on 07/11/2022 by the Ethics Committee Essen, Germany (number 22-10805-BO). Findings will be published in peer-reviewed open-access journals and presented at local, national and international conferences.Trial registration numberGerman Clinical Trials Registry (number DRKS00030683).

show abstract

Prospective, Longitudinal Study on Specific Cellular Immune Responses after Vaccination with an Adjuvanted, Recombinant Zoster Vaccine in Kidney Transplant Recipients

Cited by 7 publications

References 34 publications

Long-Term Follow-Up after Adoptive Transfer of BK-Virus-Specific T Cells in Hematopoietic Stem Cell Transplant Recipients

Long-Term Follow-Up after Adoptive Transfer of BK-Virus-Specific T Cells in Hematopoietic Stem Cell Transplant Recipients

Current Perspectives on the Management of Herpesvirus Infections in Solid Organ Transplant Recipients

Tiza–Titre increase and enhanced immunity through an adjuvanted, recombinant herpes zoster subunit vaccine in patients with liver cirrhosis and post-liver transplantation: a study protocol for a prospective cohort study

Contact Info

Product

Resources

About